Chimerix Announces Positive Topline Results for ONC201 in Recurrent H3 K27M-mutant Glioma
November 04, 2021 07:00 ET
|
Chimerix, Inc.
– Blinded Independent Central Review (BICR) of ONC201 Cohort Reported 20.0% Objective Response Rate (ORR) by RANO-HGG Criteria – – Compelling Durability of Responses with 11.2 Month Median Duration...
Chimerix to Present at Credit Suisse 30th Annual Healthcare Conference
November 01, 2021 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Report Third Quarter 2021 Financial Results and Provide an Operational Update on November 4, 2021
October 28, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing medicines for patients facing deadly diseases that meaningfully improves and extends...
Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Reports Second Quarter 2021 Financial Results and Provides Operational Update
August 05, 2021 07:00 ET
|
Chimerix, Inc.
– Received U.S. Food and Drug Administration (FDA) Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox – – Blinded Independent Central Review (BICR) of ONC201 Registration Cohort in...
Chimerix to Present at 2021 Wedbush PacGrow Healthcare Conference
August 03, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Report Second Quarter 2021 Financial Results and Provide an Operational Update on August 5, 2021
July 29, 2021 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Receives U.S. Food and Drug Administration Approval for TEMBEXA® (brincidofovir) for the Treatment of Smallpox
June 04, 2021 14:10 ET
|
Chimerix, Inc.
DURHAM, N.C., June 04, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix to Present at Jefferies Virtual Healthcare Conference
May 25, 2021 08:00 ET
|
Chimerix, Inc.
DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...
Chimerix Announces Upcoming Presentations at the American Society of Clinical Oncology 2021 Annual Meeting
May 19, 2021 17:01 ET
|
Chimerix, Inc.
DURHAM, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases,...